Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer

The authors used in vitro and in vivo preclinical MDA prostate cancer PDX models of resistant human prostate cancer to determine molecular mechanisms of cross-resistance between anti-androgen therapy and taxane chemotherapy, underlying the therapeutically resistant phenotype.